Renaissance Technologies LLC Raises Holdings in Myomo, Inc. (NYSEAMERICAN:MYO)

Renaissance Technologies LLC lifted its stake in Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) by 39.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 199,600 shares of the company's stock after purchasing an additional 56,500 shares during the quarter. Renaissance Technologies LLC owned about 0.66% of Myomo worth $1,285,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC acquired a new position in shares of Myomo in the third quarter valued at about $36,000. Jane Street Group LLC purchased a new stake in Myomo in the third quarter valued at approximately $65,000. Thompson Davis & CO. Inc. acquired a new position in Myomo in the 4th quarter worth approximately $181,000. Calamos Advisors LLC purchased a new position in Myomo during the 4th quarter worth approximately $189,000. Finally, Russell Investments Group Ltd. acquired a new stake in Myomo during the 4th quarter valued at approximately $229,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Myomo Stock Performance

Shares of NYSEAMERICAN MYO opened at $4.81 on Tuesday. The stock has a market cap of $145.50 million, a price-to-earnings ratio of -20.91 and a beta of 1.68. Myomo, Inc. has a one year low of $2.76 and a one year high of $7.17. The business has a fifty day moving average of $4.86.

Insider Transactions at Myomo

In other news, insider Micah Mitchell sold 48,000 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the completion of the sale, the insider now directly owns 140,572 shares in the company, valued at $725,351.52. This represents a 25.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas F. Kirk purchased 7,400 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the director now directly owns 255,933 shares of the company's stock, valued at $1,279,665. The trade was a 2.98 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 4.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MYO shares. Craig Hallum increased their price objective on shares of Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, March 11th. Ascendiant Capital Markets lifted their price objective on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, March 17th. Alliance Global Partners restated a "buy" rating on shares of Myomo in a research note on Tuesday, March 11th. Finally, HC Wainwright lifted their price target on Myomo from $7.50 to $9.50 and gave the company a "buy" rating in a research report on Wednesday, March 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $9.75.

Myomo Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.